Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a ...

New personalized skin cancer treatment shows success in preventing return of high-risk melanoma - Patients with severe ...

Platinum-resistant ovarian cancer (PROC) remains one of the most treatment-refractory malignancies, with a median overall survival (OS) of less than 12 months. Despite initial response to front-line ...

MSD awaits 20 potential launches and 80 late-stage readouts across its pipeline, which it believes will double $35bn ...